MXPA02008967A - Tratamiento de hipertension ocular y glaucoma. - Google Patents

Tratamiento de hipertension ocular y glaucoma.

Info

Publication number
MXPA02008967A
MXPA02008967A MXPA02008967A MXPA02008967A MXPA02008967A MX PA02008967 A MXPA02008967 A MX PA02008967A MX PA02008967 A MXPA02008967 A MX PA02008967A MX PA02008967 A MXPA02008967 A MX PA02008967A MX PA02008967 A MXPA02008967 A MX PA02008967A
Authority
MX
Mexico
Prior art keywords
prostaglandins
hydroxy
group
alkyl
compound related
Prior art date
Application number
MXPA02008967A
Other languages
English (en)
Spanish (es)
Inventor
Ryuji Ueno
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/730,830 external-priority patent/US20010034355A1/en
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of MXPA02008967A publication Critical patent/MXPA02008967A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA02008967A 2000-03-16 2001-03-15 Tratamiento de hipertension ocular y glaucoma. MXPA02008967A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52757300A 2000-03-16 2000-03-16
US09/730,830 US20010034355A1 (en) 2000-03-16 2000-12-07 Treatment of ocular hypertension
PCT/JP2001/002035 WO2001068072A2 (en) 2000-03-16 2001-03-15 Composition for use in treatment of ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
MXPA02008967A true MXPA02008967A (es) 2003-02-12

Family

ID=27062443

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02008967A MXPA02008967A (es) 2000-03-16 2001-03-15 Tratamiento de hipertension ocular y glaucoma.

Country Status (18)

Country Link
US (1) US20010056104A1 (enExample)
EP (1) EP1272194A2 (enExample)
JP (1) JP2003526660A (enExample)
KR (1) KR20080012407A (enExample)
CN (1) CN100506232C (enExample)
AR (1) AR029818A1 (enExample)
AU (2) AU4114301A (enExample)
BR (1) BR0109192A (enExample)
CA (1) CA2402597C (enExample)
CZ (1) CZ20023092A3 (enExample)
HU (1) HUP0300391A3 (enExample)
IL (1) IL151683A0 (enExample)
MX (1) MXPA02008967A (enExample)
NO (1) NO20024381L (enExample)
NZ (1) NZ521325A (enExample)
RU (1) RU2002127733A (enExample)
TW (1) TWI286932B (enExample)
WO (1) WO2001068072A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997022689A1 (en) † 1995-12-18 1997-06-26 Myriad Genetics, Inc. Chromosome 13-linked breast cancer susceptibility gene
US20020035148A1 (en) * 2000-07-20 2002-03-21 Ryuji Ueno Treatment of ocular hypertension
US6713268B2 (en) * 2001-06-26 2004-03-30 Allergan, Inc. Methods of identifying ocular hypotensive compounds having reduced hyperpigmentation
EP1411950A2 (en) * 2001-07-31 2004-04-28 Sucampo AG Treatment of ocular hypertension and glaucoma
AU2003215820A1 (en) * 2002-03-28 2003-10-13 Sucampo Ag Method for treating ocular hypertension and glaucoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3876050T2 (de) * 1987-09-18 1993-03-25 Ueno Seiyaku Oyo Kenkyujo Kk Okulare hypotensivagenzien.
ES2213504T1 (es) * 1988-09-06 2004-09-01 Pfizer Health Ab Derivados de prostaglandina para el tratamiento del glaucoma o hipertension ocular.
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2039420C (en) * 1990-04-04 1996-12-10 Ryuji Ueno Treatment of cataract with 15-keto-prostaglandin compounds
AU687906B2 (en) * 1993-12-15 1998-03-05 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
US6232344B1 (en) * 1997-12-22 2001-05-15 Alcon Laboratories, Inc. 13-Oxa prostaglandins for the treatment of glaucoma and ocular hypertension
ATE245451T1 (de) * 1998-04-07 2003-08-15 Alcon Lab Inc Xanthangummi enthaltende gelbildende ophthalmische zusammensetzungen

Also Published As

Publication number Publication date
AU4114301A (en) 2001-09-24
KR20080012407A (ko) 2008-02-11
NO20024381L (no) 2002-11-15
TWI286932B (en) 2007-09-21
HUP0300391A3 (en) 2008-05-28
IL151683A0 (en) 2003-04-10
HUP0300391A2 (hu) 2003-06-28
CA2402597A1 (en) 2001-09-20
CN100506232C (zh) 2009-07-01
CA2402597C (en) 2011-04-26
CN1429112A (zh) 2003-07-09
EP1272194A2 (en) 2003-01-08
CZ20023092A3 (cs) 2003-05-14
RU2002127733A (ru) 2004-03-27
WO2001068072A3 (en) 2002-06-06
NZ521325A (en) 2004-05-28
WO2001068072A2 (en) 2001-09-20
US20010056104A1 (en) 2001-12-27
JP2003526660A (ja) 2003-09-09
NO20024381D0 (no) 2002-09-13
BR0109192A (pt) 2003-05-27
AR029818A1 (es) 2003-07-16
AU2001241143B2 (en) 2005-08-25

Similar Documents

Publication Publication Date Title
EP2656845A1 (en) Composition for modulating stem cell growth with prostaglandins
JP2012197308A (ja) 眼科用組成物
JP2004504350A (ja) 高眼圧症および緑内障処置用組成物
US6458836B1 (en) Treatment of ocular hypertension and glaucoma
CA2402597C (en) Composition for use in treatment of ocular hypertension and glaucoma
CA2042937C (en) Treatment of ocular hypertension with a synergistic combination
RU2548762C2 (ru) Способ и композиция для лечения дегенерации желтого пятна
AU2001241143A1 (en) Composition for use in treatment of ocular hypertension and glaucoma
US20050014837A1 (en) Method for treating ocular hypertension and glaucoma
US20010034355A1 (en) Treatment of ocular hypertension
US20030060511A1 (en) Method for treatment of ocular hypertension and glaucoma
WO2003082257A2 (en) Method for treating ocular hypertension and glaucoma
AU2002326160A1 (en) Method and composition for treatment of ocular hypertension and glaucoma
HK1196278A (en) Method for treating schizophrenia
AU2002255346A1 (en) Method for treatingocular hypertension and glaucoma

Legal Events

Date Code Title Description
FG Grant or registration